Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Severe asthma and asthma-chronic obstructive pulmonary disease syndrome – Authors’ reply

We thank Yang Xia and colleagues for their interest in the recently published finding1 that dupilumab added to medium-dose to high-dose inhaled corticosteroids plus a long-acting β2-agonist in adults with uncontrolled persistent asthma improved lung function, reduced severe exacerbation rates, improved quality-of-life measures, and was generally well tolerated. Xia and colleagues suggested that some patients in the pivotal asthma phase 2b study met criteria for asthma-chronic obstructive pulmonary disease overlap syndrome and that these patients could also benefit from dupilumab treatment.

email